EBOVAC3, Bringing a prophylactic Ebola vaccine to licensure

Summary

The EBOVAC3 project aims to assess, through clinical trials in children and adults in Africa, the safety and effectiveness of an Ebola vaccine regimen. As such it will help to improve the world’s preparedness to deal with an Ebola outbreak. The project focuses on the ‘prime-boost’ Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) prime-boost’ Ebola vaccine regimen, in which patients are first given a dose to prime the immune system, and then a boost dose which is intended to enhance the immune response over time. Building on work carried out under the EBOVAC1 and 2 projects, EBOVAC3 will run clinical trials in children in Sierra Leone, Guinea and the Democratic Republic of Congo. It will also follow up people who participated in earlier clinical trials in Sierra Leone, to assess the safety and efficacy of the vaccine in the longer term. Finally, the project aims to characterize the outbreak preparedness of Sierra Leone, Guinea and the Democratic Republic of Congo.

Funding

IMI: 8.541.213 €

Researchers:

UA coordinator: Pierre Van Damme

UA Co-coordintor: Jean-Pierre Van geertruyden

Period

01/06/2018 - 31/05/2023

more information on EBOVAC3 website and IMI project portal

Appui scientifique pour la realization du project interdisciplinaire/interuniversitaire en santé maternelle à Unikin et à Unilub

Abstract

This project represents a formal research agreement between UA and on the other hand VLIR. UA provides VLIR research results mentioned in the title of the project under the conditions as stipulated in this contract.

Funding(s)

VLIR

Researcher(s)

Principal investigator: Van geertruyden Jean-Pierre
Co-principal investigator: Maes Louis
Co-principal investigator: Jacquemyn Yves
Co-principal investigator: Bogers John-Paul

Period:

01/12/2014-30/11/2018

Set up of HPV reference centre and establishment of HPV research network within the African.

Abstract

HPV is the main, almost unique cause of cervix carcinoma in adult women. Unfortunately, currently, many African countries lack comprehensive data on the circulating HPV types and Africa may harbor a variety of unexplored circulating HPV types which are uniquely distributed in various cancers and benign lesions.
This NSS initiative will establish a HPV research network between several VLIR partners of whom some are already conducting HPV and/or cervix carcinoma research with own VLIR-UOS funding.

Funding(s)

VLIR-UOS

Researcher(s)

Principal investigator: Bogers John-Paul, Jean-Pierre Van geertruyden

Period

13/12/2013-31/05/2015

Website

www.wakahpvafrica.com

Réduire d'épilepsie des rivières en République Démocratique du Congo

Abstract

L’épilepsie des rivières observé dans des régions hyperendémique pour l’onchocercose  est un syndrome neurologique inexpliqué. Notre hypothèse est que cette forme d’épilepsie, qui inclus le syndrome de hochement de tête (Nodding Syndrome), est causé par un pathogène encore inconnu transmis par les Simulii (l’insecte qui également transmet la cécité des rivières). Avec  notre projet nous voulons tester cette hypothèse et évaluer dans la Province Orientale de la RDC, des interventions qui puissent réduire l’incidence de cette épilepsie.

Funding

VLIR-UOS (South Initiative)

Researcher(s)

Principal investigator: Colebunders Robert
Investigator: Jean-Pierre Van geertruyden

Partner:

Prof. B. AgassaUniversité de Kisangani, RD Congo

Nodding Syndrome: a trans-disciplinary approach to identify the cause and decrease the incidence of river epilepsy (NSETHIO)

Abstract:

Nodding syndrome (NS) is a neurological, incurable syndrome, currently affecting mainly children between 5 and 15 years of age in South Sudan, Uganda and Tanzania. Since 1950, when NS was first described, its cause has remained a mystery. NS is characterized by head-nodding (an atonic form of epilepsy), often followed by clonic - tonic seizures, developmental retardation and faltering growth. In the affected regions, NS is a major public health problem associated with severe socio-economic consequences. After exploratory missions to South Sudan, Uganda and the Democratic Republic of the Congo (DRC), we gathered epidemiological evidence that supports the hypothesis that NS is a disease caused by a pathogen transmitted by blackflies, the vectors that transmit the parasitic worm that causes onchocerciasis. We hypothesise that the same disease is also endemic in other onchocerciasis hyper-endemic regions e.g. in the Mbam valley, Cameroon and the Orientale Province, DRC (where it is referred to as “river epilepsy”). In this project we aim to investigate our hypotheses in South Sudan, Uganda, Tanzania, Cameroon and the DRC with a trans-disciplinary approach including clinical-epidemiological, post-mortem, eco-entomological, and metagenomic studies. We will study the effect of vector control methods and ivermectin distribution on the incidence of river epilepsy. So far a multi-country study on NS was never done and nearly all previous studies were cross-sectional, carried out during short country visits. With this long term research plan we hope to finally discover the cause of NS and detect effective control strategies to decrease the incidence of epilepsy in onchocerciasis endemic areas.

Funding

EU, Horizon 2020

Budget

€ 2417000

Investigator:

Prof. Robert Colebunders

Partners:

Universitaetsklinikum Bonn, Germany

San Diego State University Foundation, United States

Period

1/10/2015 - 30/09/2020

Website

Reinforcement d'une unité de recherche clinique à l'UNIKIN, en République Démocratique du Congo.

Abstract

This project represents a formal research agreement between UA and on the other hand VLIR. UA provides VLIR research results mentioned in the title of the project under the conditions as stipulated in this contract.

Funding(s)

FED. INST.

Researcher(s)

Principal investigator: Van geertruyden Jean-Pierre

Period

01/06/2012-30/05/2015

Création d'une unité interdépartementale de recherche clinique à la Faculté de médecine de l'Université de Lubumbashi (UNILU)

Abstract

La RD Congo et l' l'Université de Lubumbashi (UNILU) souffrent d'une grave carence du personnel compétent en recherche scientifique clinique de qualité internationale et en relève académique; surtout en pathologies infectieuses. Ce projet initial vise à créer une unité de recherche clinique à la Faculté de médecine de l'UNILU. Pour s'y faire, ce projet permettra la formation du personnel académique dans la conduite des recherches cliniques mais aussi en épidémiologie et statistiques. La formation du personnel scientifique se concrétisera par la réalisation de 7 projets de recherches sélectionnés de manière compétitive avec un sup-port adéquat de laboratoire. Les récipiendaires bénéficieront des cours ad hoc et d'un encadrement des professeurs de l'UA, de l'UNIKIN et de l'UNILU afin de pouvoir continuer avec leur projet de recherche jusqu'au niveau doctoral.

Funding(s)

VLIR-UOS

Researcher(s)

Principal investigator: Jean-Pierre Van geertruyden

Partner:

Abdon Mukalay, Université de Lubumbashi

Period

13/03/16 - 31/12/2017